DOI: https://doi.org/10.54393/pbmj.v5i6.555

PAKISTAN BIOMEDICAL JOURNAL

https://www.pakistanbmj.com/journal/index.php/pbmj/index

Volume 5, Issue 6 (June 2022)

Review Article

Incidence and Management of Complications Associated With Myocardial Infarction

Muhammad Ahsan Waqar[1], Tehseen Riaz[1]*, Imtiaz Majeed[1], Mustafa Khurram[1], Faiza Waseem[2], Tooba Mehboob[1], Naila Tabassam[1], Rabia Aslam[1] and Irfan Bashir[1]

[1]Faculty of Pharmacy, University of Central Punjab, Lahore (UCP), Lahore, Pakistan
[2]Lahore College for Women University, Lahore, Pakistan

ARTICLE INFO

Key Words:

Congestive Heart Failure, Myocardial Infarction, Acute Myocardial Dead Tissue, Coronary Artery Disease, Pericarditis, Cardiogenic Shock

How to Cite:

Ahsan Waqar, M. ., Riaz, T., Majeed , I. ., Khurram, M. ., Waseem , F. ., Mehboob, T. . ., Tabassam, N. . ., Aslam, R. ., & Bashir, I. . (2022). Incidence And Management of Complications Associated with Myocardial Infarction: Incidence and Management of Complications Associated With Myocardial Infarction. Pakistan BioMedical Journal, 5(6). https://doi.org/10.54393/pbmj.v5i6.555

***Corresponding Author:**

Tehseen Riaz
Department of Pharmacology, University of Central Punjab, Lahore, Pakistan
tehseen.riaz@ucp.edu.pk

Received Date: 12th June, 2022
Acceptance Date: 27th June, 2022
Published Date: 30th June, 2022

ABSTRACT

Coronary heart disease (CHD) is a major cause of morbidity and mortality all around the world. Incidence of the complications of myocardial infarction (MI) had decreased to less than 1% since invention of the percutaneous coronary intervention, although the mortality results from myocardial infarction had decreased in recent years, however the burden of this disease have not ceased. Modern treatment of MI is basically built on any of the clinical evidences that are based on many of the studies that have been studied from previous thirty years. Clinical practice's evolution had significantly decreased morbidity or mortality linked by this disorder. Severe complications of the myocardial infarction include cardiogenic shock, inferior myocardial infarction, pericarditis and noteworthy right ventricular infarction. These complications are very rare; however, their reputation is neglected for the possible failure to manage early diagnosis and appropriate treatment. Inferior wall myocardial infarction accounts for 40- 50% of all the myocardial infarctions and are mostly seen as having a more promising diagnosis than the anterior wall infarctions. Pericarditis is the common disorder and a complication that arises after the myocardial infarction and has multiple causes. This is present in many secondary care and primary care settings. Frequently pericarditis has been often self-restricted, and the non-steroidal anti-inflammatory agents (NSAIDS) remains treatment of first line in the simple cases. Pharmacological management of complications includes beta blockers, Angiotensin Converting Enzyme Inhibitors, Antiplatelet Agents, and Non-Steroidal Anti-Inflammatory Drugs.

INTRODUCTION

Myocardial infarction (MI) has been the major reason of disability and death around the globe. Myocardial infarction (MI) could be the first indicator of chronic coronary artery disease (CAD), or it could have occurred frequently in the patients with already conventional illness. From the view of epidemiologically, the cause of myocardial infarction in the population could be used as for the prevalence of mainly coronary artery disease in that specified population area [1]. Physiologically myocardial infarction is defined as myocardial death of the cells, because of long term ischemia. Cell death is identified physiologically as coagulation or contraction band necrosis, which had usually evolved mainly through the oncosis, but could results in a lesser degree from apoptosis. Careful analysis of the histological sections by the experienced observer is essential to identify the entities [2]. Neurotically, cell demise is characterized mainly as coagulation and also by further compression band deterioration that typically forms by the process of oncosis, however it could result less by apoptosis. Myocardial infarction could likewise be identified as a sudden ischemic death of the myocardial tissue. Mostly in clinical settings, myocardial infarction is

DOI: https://doi.org/10.54393/pbmj.v5i6.555

Myocardial infarction (MI) has been the major reason of disability and death around the globe. Myocardial infarction (MI) could be the first indicator of chronic coronary artery disease (CAD), or it could have occurred frequently in the patients with already conventional illness. From the view of epidemiologically, the cause of myocardial infarction in the population could be used as for the prevalence of mainly coronary artery disease in that specified population area [1]. Physiologically myocardial infarction is defined as myocardial death of the cells, because of long term ischemia. Cell death is identified physiologically as coagulation or contraction band necrosis, which had usually evolved mainly through the oncosis, but could results in a lesser degree from apoptosis. Careful analysis of the histological sections by the experienced observer is essential to identify the entities [2]. Neurotically, cell demise is characterized mainly as coagulation and also by further compression band deterioration that typically forms by the process of oncosis, however it could result less by apoptosis. Myocardial infarction could likewise be identified as a sudden ischemic death of the myocardial tissue. Mostly in clinical settings, myocardial infarction is due to the thrombotic impairment of the coronary vessel that brings about by rupture of the weak plaque. Ischemia instigates noteworthy metabolic or ionic annoyances in inclined myocardium or causes the rapid depression of the systolic function [3]. Myocardial infarction has been classified into 5 sorts and was presented in 2007 as a significant segment of the all-inclusive description. Rather than the plaque burst associated with the type 1 myocardial infarction, type 2 myocardial infarction is viewed as an irregularity among the supply and demand of oxygen in the myocardium [4]. At the point when confronted with patient having intense chest ache, clinicians should recognize myocardial infarction (MI) from any remaining reasons for intense chest pain. On the off chance that MI is suspected, ongoing therapeutic treatment incorporates concluding in terms of regulating thrombolysis and essential percutaneous transluminal coronary angioplasty and to allow patients to move to CCU(coronary care unit)[5].

Mortality and Morbidity: Current management of the intense myocardial infarction (MI) is based on some clinically proof base strained from numerous investigations embraced in the course of recent many years. Advancement in the clinical practices have generously diminished mortality and morbidity related with this disorder [6]. Patients with diabetes mellitus, creating intense myocardial infarction, is the group with especially high danger of death and reinfarction [7]. Half year mortality in inferior MI was 7.8% contrasted with anterior MI recorded as13.2%. Patients suffering from inferior myocardial infarction, arrhythmias are altogether more normal in patients with RV myocardial inclusion which likewise has the pattern towards larger mortality, failure of the pump and many mechanical complications [8]. Overall danger for all reason of deaths and CVS results (cardiovascular deaths, repetitive MI) was as a minimum of 30% larger than those in the overall reference population of both from 1–3 years and from 3–5 years subsequently after the MI attack. Danger features prompting more regrettable results after MI included comorbid diabetes, hypertension and peripheral artery disease, older age, reduced renal function, and history of stroke [9].

Incidence Of Complications Associated With Myocardial Infarction In Developing And Developed Countries: In Europe, many of about 55% female deaths are being brought about by the cardiovascular diseases, particularly CHD, contrasted and 44% of every single male demise. The morbidity of CHD would increment by 146% in ladies and 174% in men in Middle East nations. In Jordan, Middle Eastern agricultural nation, as indicated by the most recent WHO report, chronic heart disease deaths came to almost 19% of all out deaths. Deaths rate per 100,000 because of CHD is 131 of all the population, finishing to make Jordan to be positioned number 46 on the planet. Estimated at every 25 seconds regular intervals an American will have a CVD event. Acute myocardial dead tissue (AMI) is the essential result of CHD. AMI is a main source of death in Jordan [10]. Occurrence of cardiogenic shock in the community has rapidly increased over time. Cardiogenic shock (CS) remains the major chief cause of death for patients that are admitted with myocardial infarction (MI). While, shock had often developed early after the MI onset, it is mainly not been detected on the hospital presentation [11].The evolutionary clinical practices have substantially reduced the mortality and morbidity associated with this disorder [12]. All the developing countries contribute a significant offer to the worldwide burden of cardiovascular disease. Acute myocardial infarction (AMI) specifically stays one of the main sources of death in the developing world [13].

Complications Associated With Myocardial Infarction: Complications of myocardial infarction incorporate ventricular septal rupture with acute ventricular septal defect, papillary muscle rupture with severe mitral regurgitation, acute and subacute free-wall rupture, and hemodynamically substantial right ventricular infarction. Such of the complications have been inconsistent, their significance is emphasized due to the possible capacity to address them with the early determination and for the suitable treatment. These complications are not common, their importance is neglected because they are not detected during the early diagnosis and proper treatment couldn't be provided [14]. Significant complications of the acute myocardial infarction are right ventricular

DOI: https://doi.org/10.54393/pbmj.v5i6.555

myocardial infarction, rupture of the free wall and pseudo aneurysm, rupture of the ventricular septum, cardiogenic shock, infarct expansion or extension, acute mitral regurgitation, pericarditis, peri-infarction hypertension, bradyarrhythmias and tachyarrhythmia. For every one of the diseases, rules for the diagnosis and for the treatment is advertised [15].

Cardiogenic Shock: Cardiogenic shock (CS) is a basic disorder of the end organ hypoperfusion brought about by essential heart illness, with up to 80% brought about by intense myocardial infarction (AMI). Notwithstanding standard treatments for AMI-CS including reperfusion and vasoactive aids, mechanical circulatory support (MCS) gadgets are frequently utilized to diminish the myocardial oxygen demand, lessen left ventricular divider stress, and consequently help in myocardial recuperation [16]. In patients with the cardiogenic shock, crisis revascularization didn't essentially lessen generally mortality at 30 days. Nonetheless, following a half year there was a serious existence benefit. Early revascularization ought to be unequivocally measured for the patients with myocardial infarction confounded via cardiogenic shock (CS) [17]. Patients in whom cardiogenic shock created had an essentially more serious danger of death on during hospitalization (71.7 %) than the individuals who didn't have cardiogenic shock. The frequency of cardiogenic shock continued generally stable after some time, averaging 7.1 percent among the patients with myocardial infarction [18].



Figure 1 : Recommendations for initial reperfusion therapy when CS complicates Acute MI



Figure 2: Classic shock paradigm, as illustrated by S. Hollenberg, is shown in black. The influence of the inflammatory response syndrome initiated by a large MI is illustrated in red. LVEDP indicates left ventricular end-diastolic pressure.

Inferior Wall Myocardial Infarction: Inferior myocardial infarctions represent 40-50% of all intense myocardial infarctions and are for the most part seen as having a more good visualization than foremost divider areas of dead tissue [20]. According to a study, around 40- 50% of all myocardial infarctions are inferior wall myocardial infarction and are usually considered as to be more promising prognosis than anterior wall infarctions [21]. Inferior infarction is viewed as less broad than front and normally of short emergency clinic stay, great visualization and not many in-medical clinic difficulties. Be that as it may, a significant number of significant difficulties when occurred during intense mediocre dead tissue like total heart block, tricuspid or mitral worth ineptitude and ventricular septal imperfections may entangle this less broad nature of localized necrosis and delay medical clinic stay, increment in-medical clinic complexities and mortality to about twice higher when contrasting and sub-par dead tissue who didn't have these intricacies at the hour of their introduction or a short time later during CCU stay.

Right Ventricular Infarction: Patients suffering from inferior MI who had right ventricular (RV) myocardial inclusion seem +to having a more terrible prognosis than the individuals who don't had RV contribution. Be that as it may, past investigations have been restricted by little patient numbers. Right ventricular infarction arises 14% in patients suffering from myocardial infarction. This mainly occurs exclusively as a complication of posterior left ventricular infarction [22]. The chief reason for right ventricular infarction includes the atherosclerotic posterior obstruction in the right coronary artery. Posterior impediment of the artery prompts electrocardiographically recognizable of the right heart ischemia or an expanded danger of severe damage within sight of the acute inferior infarction. Hemodynamic impacts in the right ventricular damage might incorporate dysfunction in right ventricle to siphon enough blood in the aspiratory circuit to one side ventricle, with ensuing systemic hypotension. Treatment mainly includes the concerns towards, volume loading, reperfusion, rhythm and rate control, and mainly inotropic support [23]

Free Wall Myocardial Rupture : In patients with the myocardial infarction, left ventricular free wall rupture has been an infrequent complexity (2–4%) however it is related with a large mortality from the pericardial tamponade [24]. Ventricular free-wall rupture stays one of the main sources of death after myocardial infarction (MI). With expanded capacities for conclusion and revival procedures, careful

DOI: https://doi.org/10.54393/pbmj.v5i6.555

adjustment of free-wall myocardial imperfections coming about because of ischemia and rot may turn into a basic methodology of treatment, bringing about progress of the endurance rate [25]. There are various danger pointers that are related with cardiac rupture, for example, female sexual orientation, mature age, hypertension, and first MI. Common indications of heart crack are repetitive or constant chest pain, syncope, and distension of jugular veins. Electrocardiographic signs may incorporate sinus tachycardia, new Q-waves in at least 2 leads, tenacious or intermittent ST section height, deviation of expected developmental T-wave design, and electromechanical separation in end-stage cases [26].

Pericarditis: Acute pericarditis, irritation of the pericardium, is found in around 5% of patients admitted to department of emergency for chest torment somewhat unrelated to the acute myocardial infarction. It happens frequently in men 20 to 50 years old. Patients with intense pericarditis regularly present with intense, sharp, retrosternal chest torment that is eased by sitting or inclining forward. Glucocorticoids are customarily saved for extreme or stubborn cases, or in situations when the reason for pericarditis is likely connective tissue infection, autoreactivity, or uremia. Cardiology discussion is suggested for patients with extreme illness, those with pericarditis recalcitrant to empiric treatment, and those with indistinct etiologies [27]. Pericarditis is mainly a communal disorder and a complication that arises after the myocardial infarction and has multiple causes. This is present in various secondary care and primary care cases. Pericarditis has been frequently often self-restraining, and non-steroidal anti-inflammatory agents (NSAIDS) remain the treatment of first line for simple cases [28]. Patients with the acute pericarditis ought to be dealt with exactly with nonsteroidal mitigating drugs. Colchicine might be utilized as monotherapy or in blend with a nonsteroidal mitigating drug for the primary scene of intense pericarditis [29].

PHARMACOLOGICAL MANAGEMENT

Although complications of myocardial infarction are not properly treatable, but are manageable by the help of following agents.

Beta Blockers: Beta-blockers address an exceptional progression in pharmacotherapy. Beta-blockers are quite possibly the most broadly utilized class of medications in cardiovascular medication for patients with coronary illness, arrhythmias, heart failure (HF), and hypertension [30]. The early utilization of beta-blockers is related with diminished rate of CR, recommending some advantageous impacts of beta-blockers on infarct mending after the acute MI [31].

Angiotensin Converting Enzyme Inhibitors: At the point when initially presented, Angiotensin-converting enzyme (ACE) inhibitors in 1981 were shown uniquely for the treatment of the refractory high blood pressure. From that point forward, these mainly have been appeared to lessen the mortality or morbidity in congestive heart failure, myocardial infarction, chronic renal insufficiency, diabetes mellitus, and atherosclerotic cardiovascular disease [32]. Angiotensin-converting enzyme inhibitors have acquired the place alongside aspirin, β-blockers, and thrombolytic agents as clinical treatments demonstrated to decrease death rates in intense myocardial infarction [33].

Antiplatelet Agents: Antiplatelet agents are recommended generally for essential and secondary prevention of the cardiovascular illness in Western nations to diminish the frequency of intense cerebro-and cardiovascular occasions. These occasions are firmly connected to the shakiness of atheromatous plaques and to the thrombogenicity of blood. For instance, more than 66% of the unexpected heart occasions (intense coronary condition or abrupt cardiovascular demise) and half of the postoperative myocardial infarctions (MIs) are because of the interruption and thrombosis of an unstable plaque [34]. Antiplatelet treatment diminishes genuine vascular events and vascular demise in patients with Peripheral vascular infection. There is likewise proof to help the utilization of the antiplatelet drugs other than aspirin for the counteraction of vascular occasions in those with PVD [35].

Non-Steroidal Anti-Inflammatory Drugs: Utilization of some nonsteroidal anti-inflammatory drugs (NSAIDs) is related with expanded cardiovascular risk in a few of the patient groups, however whether this abundance hazard exists in evidently solid people has not been explained [36]. An expanded danger of cardiovascular occasions among all and new current clients of rofecoxib, valdecoxib, and indomethacin in patients with no set of history of the CVD [37].

Non-Pharmacological Management: Poor diet quality, including overabundance of the caloric ingestion and some unnatural food decisions, decreased physical acts and psychological pressure, are some of the major adjustable way of life factors that are likely to cause the disease transmission of HF [38]. Cell transplantation, LV restriction gadgets, and tissue designing methodologies have arisen as potential options in contrast to heart transplantation for the treatment of ruptured myocardium. Later methodologies incorporate the utilization of in vitro designed tissue, which is refined in vitro and afterward embedded in vivo, and in situ designed tissue, which is infused directly into the myocardium. Polymer networks have additionally been used to forestall LV expansion [39]. The frequency of MI in different parts of the world is being

DOI: https://doi.org/10.54393/pbmj.v5i6.555

influenced by demographic qualities and way of life of the people. It should be a hazardous sickness by patients and they property it to their way of life. Conduct hazard factors are frequently related and closer adherence to a better way of life may lessen the danger of coronary illness. A few examinations show that way of life change forestalls as well as controls the advancement of heart illnesses and decreases the event of cardiovascular occasions in the patients with cardiovascular infections. Way of life alteration to forestall the occurrence of coronary vascular issues is among the fundamental projects of WHO. Picking a sound way of life alongside a decent eating regimen lessen the pace of MI and the need to a medical procedure and angioplasty. Despite the accessibility of boundless examinations with respect to the significance of improving the danger factors and changing the way of life after MI, about portion of the patients experience a few difficulties like further MI three years after it on the grounds that changing the way of life is troublesome. One of the issues of patients with intense MI is making change in their way of life during a brief timeframe [40].

CONCLUSIONS

Above literature shows that the medications provided to the patients with the complications are mostly manageable and are not treatable completely. These complications could arise in the patients after the MI attack. There have been many of the consistent and advanced developments in the materialistic movements for the enduring survivals and many cardiovascular consequences afterward MI attack. Many MI survivor remains at the larger hazards than general population, especially for the population with all the additional advanced hazard features such as hypertension, diabetes, or older age. However, there are some interventions that could be done to minimize the complications that are associated with myocardial infarction.

REFERENCES

[1] Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). European heart journal. 2019Jan14;40(3):23769.doi.10.1093/eurheartj/ehy462

[2] Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Journal of the American College of Cardiology. 2007 Nov; 50(22):2173-95. doi.10.1161/CIRCULATIONAHA.107.187397

[3] Frangogiannis N G, Pathophysiology of Myocardial Infarction. Compr Physiol, 2015. 5(4): p. 1841-75. doi.10.1002/cphy.c150006

[4] Saaby L, Poulsen TS, Hosbond S, Larsen TB, Diederichsen AC, Hallas J, Thygesen K, Mickley H. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. The American journal of medicine. 2013 Sep; 126(9):789-97. doi.10.1016/j.amjmed.2013.02.029

[5] Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. Is this patient having a myocardial infarction?. Jama. 1998Oct;280(14):125663.doi.10.1001/jama.280.14.1256

[6] White HD, Chew DP. Acute myocardial infarction. The Lancet.2008Aug;372(9638):57084.doi.10.1016/S0140-6736(08)61237-4

[7] Herlitz J, Malmberg K, KARLSON BW, RYDÉN L, HJALMARSON Å. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Medica Scandinavica. 1988 Jan 12;224(1):31-8. doi.10.1111/j.0954-6820.1988.tb16735.

[8] Athanasuleas CL, Stanley AW, Buckberg GD, Dor V, DiDonato M, Blackstone EH, et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. Journal of the American College of Cardiology. 2001 Apr; 37(5):1199-209. doi.10.1016/S0735-1097(00)01089-5

[9] Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovascular Disorders. 2017 Dec ;17(1):1-8. doi.10.1186/s12872-017-0482-9

[10] AbuRuz ME, Al-Dweik G. Depressive symptoms and complications early after acute myocardial infarction: gender differences. The Open Nursing Journal. 2018;12:205. doi.10.2174/1874434601812010205

[11] Menon V and J S Hochman, Management of cardiogenic shock complicating acute myocardial infarction. Heart. 2002 Nov; 88(5):531-7. doi.10.1136/heart.88.5.531

[12] Anderson J L and D A Morrow, Acute myocardial infarction. New England Journal of Medicine. 2017 May 25;376(21):2053-64. doi.10.1056/NEJMra1606915

[13] Abdallah MH, Arnaout S, Karrowni W, Dakik HA. The management of acute myocardial infarction in developing countries. International journal of cardiology. 2006 Aug 10;111(2):189-94. doi.10.1016/j.ijcard.2005.11.003

[14] Reeder GS. Identification and treatment of complications of myocardial infarction. InMayo Clinic Proceedings. Elsevier. 1995 Sep; 70(9): 880-4). doi.10.1016/S0025-6196(11)63946-3

[15] Lavie C J and B J Gersh. Mechanical and electrical

DOI: https://doi.org/10.54393/pbmj.v5i6.555

complications of acute myocardial infarction. in Mayo Clinic Proceedings. Elsevier. 1990 May; 65(5):709-730). doi.10.1016/S0025-6196(12)65133-7

[16] Vallabhajosyula S, Subramaniam AV, Murphree Jr DH, Patlolla SH, Ya'Qoub L, Kumar V, et al. Complications from percutaneous-left ventricular assist devices versus intra-aortic balloon pump in acute myocardial infarction-cardiogenic shock. PloS one. 2020 Aug; 15(8):e0238046. doi.10.1371/journal.pone.0238046

[17] Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. New England Journal of Medicine. 1999 Aug; 341(9):625-34. doi.10.1056/NEJM199908263410901

[18] Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. New England Journal of Medicine. 1999 Apr; 340(15):1162-8. doi.10.1056/NEJM199904153401504

[19] Tehrani BN, Truesdell AG, Psotka MA, Rosner C, Singh R, Sinha SSet al. A standardized and comprehensive approach to the management of cardiogenic shock. Heart Failure. 2020 Nov; 8(11):879-91. doi.10.1016/j.jchf.2020.09.005

[20] Berger PB, Ryan TJ. Inferior myocardial infarction. High-risk subgroups. Circulation. 1990 Feb; 81(2):401-11. doi.10.1161/01.CIR.81.2.401

[21] Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, Lindley KJ, Vaccarino V, Wang TY, Watson KE, Wenger NK. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 2016 Mar 1;133(9):916-47. doi.org/10.1161/CIR.0000000000000351

[22] Kinch JW, Ryan TJ. Right ventricular infarction. New England Journal of Medicine. 1994 Apr 28;330(17):12117.doi.10.1056/NEJM199404283301707

[23] Horan LG, Flowers NC. Right ventricular infarction: specific requirements of management. American Family Physician. 1999 Oct; 60(6):1727.

[24] Figueras J, Cortadellas J, Soler-Soler J. Left ventricular free wall rupture: clinical presentation and management. Heart. 2000 May; 83(5):499-504. doi.10.1136/heart.83.5.499

[25] Pappas PJ, Cernaianu AC, Baldino WA, Cilley Jr JH, DelRossi AJ. Ventricular free-wall rupture after myocardial infarction:treatmentandoutcome.Chest. 1991 Apr; 99(4):892-5. doi.10.1378/chest.99.4.892

[26] Wehrens XH, Doevendans PA. Cardiac rupture complicating myocardial infarction. International journal of cardiology. 2004 Jun; 95(2-3):285-92. doi.10.1016/j.ijcard.2003.06.006

[27] Snyder MJ, Bepko J, White M. Acute pericarditis: diagnosis and management. American family physician. 2014 Apr; 89(7):553-60.

[28] Troughton RW, Asher CR, Klein AL. Pericarditis. The Lancet. 2004 Feb; 363(9410):717-27. doi.10.1016/S0140-6736(04)15648-1

[29] Imazio M, Trinchero R. Triage and management of acute pericarditis. International journal of cardiology. 2007Jun;118(3):28694.doi.10.1016/j.ijcard.2006.07.100

[30] Harari R, Bangalore S. Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!. European Heart Journal. 2020 Oct 1;41(37):3530-2. doi.10.1093/eurheartj/ehaa436

[31] Gong W, Feng S, Wang X, Fan J, Li A, Nie SP. Beta-blockers reduced the risk of cardiac rupture in patients with acute myocardial infarction: A meta-analysis of randomized control trials. International Journal of Cardiology. 2017 Apr; 232:171-5. doi.10.1016/j.ijcard.2017.01.035

[32] Bicket DP. Using ACE inhibitors appropriately. American family physician. 2002 Aug 1;66(3):461.

[33] Pfeffer MA. ACE inhibitors in acute myocardial infarction: patient selection and timing. Circulation. 1998 Jun; 97(22):2192-4. doi.10.1161/01.CIR.97.22.2192

[34] Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. British Journal of Anaesthesia. 2007 Sep; 99(3):316-28. doi.10.1093/bja/aem209

[35] Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. British JournalofSurgery.2001Jun;88(6):787800.doi.10.1046/j.0007-1323.2001.01774.x

[36] Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clinical Pharmacology & Therapeutics. 2009 Feb; 85(2):190-7. doi10.1038/clpt.2008.204

[37] Roumie CL, Choma NN, Kaltenbach L, Mitchel, Jr EF, Arbogast PG, Griffin MR. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events–stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiology and Drug Safety. 2009 Nov; 18(11):1053-63. doi.10.1002/pds.1820

[38] Aggarwal M, Bozkurt B, Panjrath G, Aggarwal B, Ostfeld RJ, Barnard ND, Gaggin H, Freeman AM, Allen

DOI: https://doi.org/10.54393/pbmj.v5i6.555

K, Madan S, Massera D. Lifestyle modifications for preventing and treating heart failure. Journal of the American College of Cardiology. 2018 Nov; 72(19):2391-405. doi.10.1016/j.jacc.2018.08.2160

[39] Christman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. Journal of the American CollegeofCardiology.2006Sep;48(5):90713.doi.10.1016/j.jacc.2006.06.005

[40] Molazem Z, Rezaei S, Mohebbi Z, Ostovan MA, Keshavarzi S. Effect of continuous care model on lifestyle of patients with myocardial infarction. ARYA atherosclerosis. 2013 May; 9(3):186.